ALZN
Alzamend Neuro Inc

5,915
Loading...
Loading...
News
all
press releases
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.
Stocktwits·4mo ago
News Placeholder
More News
News Placeholder
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·8mo ago
News Placeholder
Alzamend Neuro to Present at the Sequire Investor Summit
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·9mo ago
News Placeholder
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·10mo ago
News Placeholder
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·10mo ago
News Placeholder
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·11mo ago
News Placeholder
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects. read more...
Benzinga·11mo ago
News Placeholder
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago
News Placeholder
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago
News Placeholder
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago

Latest ALZN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.